Category: CSV/CSA

This category can only be viewed by members. To view this category, sign up by purchasing MEMBER PLUS + or MEMBER PLUS 6M FREE.

Presented by:Frank Meledandri Sr., Associate Director, Quality Strategy Quality Management, BDRoy Devine, GPO Computer System Validation, BDModerator:Jason Spiegler, SVP of Strategy, Sales, and Marketing, Compliance GroupBD’s Roy Devine and Frank Meledandri Sr will share their experiences in driving a risk-based CSA methodology. In addition to touching on procedural and cultural change, they will share aspects […]

Emerging technologies are quickly playing a greater role in how the Pharmaceutical and Life Sciences Industry collects, stores and interprets its data. Mixed Reality platforms are becoming more widespread in the application of displaying andinterrogating this data. This paper summarises the trials of an initiative supported by KENX USA, TU Dublin and BioPharmaChem Ireland (BPCI). […]

To access this post, you must purchase MEMBER PLUS + or MEMBER PLUS 6M FREE.

The Food and Drug Administration (FDA) has recently proposed dramatic changes to the current Computerized System Validation (CSV) approach that is being used by most companies in the Life Science Industry. Although not yet released, the proposed Computer Software Assurance for Manufacturing, Operations, and Quality System (CSA) guidance will assist manufacturers overcome several barriers to […]

To access this post, you must purchase MEMBER PLUS + or MEMBER PLUS 6M FREE.

Software as a Service (SaaS) is a cloud computing delivery model that promises various benefits, but also comes with unique risks. The life science sector has very slow cloud adoption rate. One of the potential reasons for this phenomenon, as highlighted by GAMP Cloud Special Interest Group (SIG ) is the lack of regulatory and […]

To access this post, you must purchase MEMBER PLUS + or MEMBER PLUS 6M FREE.

In 2018, the FDA released “Data Integrity and Compliance with Drug cGMP, Questions and Answers, Guidance for Industry.” Between 2015 and 2019, the number of 483 observations written globally increased by more than 10%. The increase indicates that either the industry is still catching up to compliance expectations or the FDA is inspecting with greater […]

To access this post, you must purchase MEMBER PLUS + or MEMBER PLUS 6M FREE.